A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Conditions

• Type 2 Diabetes (T2D)

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• NNC0487-0111 subcutanous — DRUG
  NNC0487-0111 administered subcutanously (under the skin)
• Placebo (NNC0487-0111 subcutanous) — DRUG
  NNC0487-0111 placebo administered subcutanously (under the skin)
• NNC0487-0111 oral — DRUG
  NNC0487-0111 administered orally (in the mouth)
• Placebo (NNC0487-0111 oral) — DRUG
  NNC0487-0111 placebo administered orally (in the mouth)

Study Details

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Key Dates

Start date

Aug 7, 2024

Status verified

Dec 2025

Primary completion

Oct 1, 2025

Completion

Oct 24, 2025

Study Design

Enrollment

448 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo subcutaneous
  Placebo for subcutaneous treatment
• Experimental: NNC0487-0111 subcutaneous dose 1
  NNC0487-0111 subcutaneous dose 1 treatment
• Experimental: NNC0487-0111 subcutaneous dose 2
  NNC0487-0111 subcutaneous dose 2 treatment
• Experimental: NNC0487-0111 subcutaneous dose 3
  NNC0487-0111 subcutaneous dose 3 treatment
• Experimental: NNC0487-0111 subcutaneous dose 4
  NNC0487-0111 subcutaneous dose 4 treatment
• Experimental: NNC0487-0111 subcutaneous dose 5
  NNC0487-0111 subcutaneous dose 5 treatment
• Experimental: NNC0487-0111 subcutaneous dose 6
  NNC0487-0111 subcutaneous dose 6 treatment
• Placebo Comparator: Placebo oral
  Placebo for oral treatment
• Experimental: NNC0487-0111 oral dose 1
  NNC0487-0111 oral dose 1 treatment
• Experimental: NNC0487-0111 oral dose 2
  NNC0487-0111 oral dose 2 treatment
• Experimental: NNC0487-0111 oral dose 3
  NNC0487-0111 oral dose 3 treatment

Primary Outcome Measure

Change in HbA1c [ Time Frame: From baseline (week 0) to end of treatment (week 36) ]

Locations (28)

Find similar trials in Santa Ana, CA

Related Studies

• Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy
  Enrolling By Invitation · Kaiser Permanente · Pleasanton, California
• Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
  Recruiting · DreaMed Diabetes · Albany, New York